<DOC>
	<DOC>NCT01907100</DOC>
	<brief_summary>This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.</brief_summary>
	<brief_title>Nintedanib (BIBF 1120) in Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criteria: Histologically confirmed malignant pleural mesothelioma (MPM) (Epithelioid or biphasic subtype for Phase II patients; epithelioid subtype only for Phase III patients) Life expectancy of at least 3 months in the opinion of the investigator Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 Measurable disease according to modified RECIST (Response Evaluation Criteria In Solid Tumours) criteria Exclusion criteria: Previous systemic chemotherapy for MPM Prior treatment with nintedanib or any other prior line of therapy Phase II patients with sarcomatoid subtype MPM or Phase III patients with biphasic or sarcomatoid subtype MPM Patients with symptomatic neuropathy Radiotherapy (except extremities) within 3 months prior to baseline imaging Active brain metastases (e.g. stable for &lt; 4 weeks) Radiographic evidence of cavitary or necrotic tumours or local invasion of major blood vessels by MPM Significant cardiovascular diseases Inadequate hematologic, renal, or hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>